About Glycom
The Glycom team
HMO donations and samples
Opportunities at Glycom
Contact us

Our lead HMOs have been approved for use in foods in Europe and the US. We also have a rich pipeline of other HMOs in early stages of development.

 European Union

In early 2016 EFSA has confirmed the safety of Glycom’s leading ingredients 2’-fucosyllactose (2’-FL) and lacto-N-neotetraose (LNnT) in infant and follow-on formulas, processed cereal-based food and baby foods for infants and young children and a range of other food applications. The positive EFSA opinions were followed by the marketing approvals as is provided by the European Commission through publication of the Implementing Decisions which lay down the uses, use levels and specifications of the Novel Foods.

These ingredients where initially produced by chemical synthesis but the Irish Food Safety Authority (FSAI) has recently confirmed that the identical high purity ingredients are substantially equivalent when produced via cell fermentation.

For EFSA opinions confirming safety see:

LNnT www.efsa.europa.eu/en/efsajournal/pub/4183

2’-FL www.efsa.europa.eu/en/efsajournal/pub/4184

For Commission Implementing Decisions authorizing the marketing see:

LNnT http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32016D0375

2’-FL http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32016D0376

For Substantial Equivalence Opinions:

LNnT    Entry 359 of Commission List of Novel Food Notifications


2’-FL    Entry 339 of Commission List of Novel Food Notifications



Danish HMO company invests more than 500m DKK in Jutland production facility

(13 January 2016)


In order to supply the vibrant HMO market in coming years, Danish biotech company Glycom is investing more than 500 million DKK in the acquisition and adaptation of the Vitalys manufacturing facility in Esbjerg, Denmark.  Existing Vitalys staff will be retained and total employment at the plant will more than double in the next 2 years as the facility is made ready for HMO production.  The investment has been funded by major Danish financial institutions and the existing shareholders.


According to John Theroux, CEO of Glycom, the acquisition will create a basis for significant international growth:


”We believe that HMOs represent a big opportunity to contribute to the health and well being of millions of people around the world and to create a high quality and substantial size Danish company in the process. We are already working with a high quality contract manufacturing partner, and the acquisition of Vitalys brings a second supply source and additional capacity that will insure high volume and low cost supply for our customers.”




HMOs are small fibers which are found in human milk. They create and maintain a strong gut barrier defence and healthy intestinal microbiotia in both infants and adults, and they are the biggest difference between infant formula and mother’s milk.  As a result, HMOs have the potential to address a number of global health challenges.   ”HMOs are unique, wonderful, gentle, natural compounds that offer many health benefits.  We can now manufacture them in large quantities and offer them to the world for the first time.  We are delighted to welcome the Vitalys employees to our adventure.” says John Theroux.


Glycom is a private Danish company that was founded in 2005.  It employs an international staff of technical specialists from 15 countries from its base at DTU in Lyngby.  Glycom was voted Entrepreneurial Start Up Company of the Year in Denmark in 2010.  ”Although we have a very international staff of scientific and technical specialists and our products will be sold all over the world, we are a Danish company with Danish research infrastructure in our labs and offices in Lyngby and now with Danish manufacturing infrastructure in Esbjerg.  I hope and intend that Glycom will become a great example of high quality international innovation from a world class Danish company.” says Kim Bøttkjaer, Chairman.


For further information, contact:
Glycom Chairman: Kim Bøttkjær, +45 40 45 52 13  or

Glycom CEO: John Theroux, +45 21 74 73 65 or jt@glycom.com